Filing Flows

Filing Flows › Companies › Nurix Therapeutics › Cash flow

Nurix Therapeutics cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow$614M in Q3 FY26 · $370M over twelve months

Operating cash flow$616M
Capital spending−$1.4M
Free cash flow+$614M
Cash / net income1.1×

Analysis

In Q3 FY26, Nurix Therapeutics generated $616M of operating cash flow and spent $1.4M on capital projects, leaving free cash flow of $614M. That is $674M more than in Q3 FY25 (−$60.1M).

Over the twelve months to Aug 31, 2026, operating cash flow was $379M; the largest uses were capital spending ($9.5M); besides operations, cash came from other financing ($240M), shares issued ($20.7M); the cash balance rose by $642M.

Operating cash flow was $616M against net income of $550M — 1.1× profit, cash ran ahead of reported earnings. The largest differences: payables +$20.6M, receivables −$20.0M, prepaid and other assets −$13.6M.

Free cash flow

Nurix Therapeutics: free cash flow by quarterNurix Therapeutics: free cash flow by quarter−$50.9MQ4 FY24−$64.6MQ1 FY25−$65.8MQ2 FY25−$60.1MQ3 FY25−$73.0MQ4 FY25−$73.0MQ1 FY26−$98.5MQ2 FY26$614MQ3 FY26
Operating cash flow less capital spending.
Nurix Therapeutics: operating cash flow against capital spendingNurix Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$48.8M$2.1MQ4 FY24−$61.1M$3.5MQ1 FY25−$63.2M$2.7MQ2 FY25−$57.4M$2.7MQ3 FY25−$67.8M$5.1MQ4 FY25−$71.9M$1.0MQ1 FY26−$96.6M$1.9MQ2 FY26$616M$1.4MQ3 FY26
Latest (Q3 FY26): Operating cash flow $616M, Capital spending $1.4M.

Capital allocation, year by year

Nurix Therapeutics: where the cash came from (up) and went (down), by fiscal yearNurix Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY21: Operating cash flow −$84.4MFY21: Shares issued $152MFY21: Capital spending −$5.7M$152MFY21FY22: Operating cash flow −$160MFY22: Shares issued $20.5MFY22: Capital spending −$12.2M$20.5MFY22FY23: Operating cash flow −$81.4MFY23: Shares issued $2.2MFY23: Capital spending −$8.4M$2.2MFY23FY24: Operating cash flow −$173MFY24: Shares issued $292MFY24: Capital spending −$9.3M$292MFY24FY25: Operating cash flow −$249MFY25: Shares issued $2.2MFY25: Capital spending −$14.0M$2.2MFY25
Over these 5 years operating cash flow totalled −$748M; the largest uses were operating cash flow ($748M) and capital spending ($49.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$720M
Debtnone
Net cash$720M

Nurix Therapeutics funds itself: free cash flow was $370M over the last twelve months, with $720M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Nurix Therapeutics: sources (+) and uses (−) of cash, Q3 FY26Nurix Therapeutics: sources (+) and uses (−) of cash, Q3 FY26Cash drawn (+) / kept (−)−$652MOperating cash flow$616MOther investing$33.0MShares issued$4.0MCapital spending−$1.4MOther financing$1.1M
Nurix Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 FY26Nurix Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 FY26Cash drawn (+) / kept (−)−$642MOperating cash flow$379MOther financing$240MShares issued$20.7MOther investing$10.6MCapital spending−$9.5M

From profit to cash

Nurix Therapeutics: net income to operating cash flow, Q3 FY26Nurix Therapeutics: net income to operating cash flow, Q3 FY26Net income$550MDepreciation & amortization$2.1MStock-based pay$10.8MReceivables−$20.0MPayables$20.6MDeferred revenue$93KPrepaid and other assets−$13.6MOperating cash flow$616M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26$616M−$1.4M$4.0M−$652M$614M
Q2 FY26−$96.6M−$1.9M$66K$3.5M−$98.5M
Q1 FY26−$71.9M−$1.0M$18.4M$176M−$73.0M
Q4 FY25−$67.8M−$5.1M—−$169M−$73.0M
Q3 FY25−$57.4M−$2.7M$178K$5.8M−$60.1M
Q2 FY25−$63.2M−$2.7M$6K−$8.3M−$65.8M
Q1 FY25−$61.1M−$3.5M$221K$34.1M−$64.6M
Q4 FY24−$48.8M−$2.1M$199M−$11.0M−$50.9M

Nurix Therapeutics: income statement and cash flow

Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%. The chart follows the revenue to costs, profit and cash.

Nurix Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.